{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:41:31Z","timestamp":1776998491572,"version":"3.51.4"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2022MH305"],"award-info":[{"award-number":["ZR2022MH305"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2019MC026"],"award-info":[{"award-number":["ZR2019MC026"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2023QH080"],"award-info":[{"award-number":["ZR2023QH080"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373097"],"award-info":[{"award-number":["82373097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403299"],"award-info":[{"award-number":["82403299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Double-Hundred Project and Taishan Scholarship","award":["WSR2023085"],"award-info":[{"award-number":["WSR2023085"]}]},{"name":"Ministry of Education \"Chunhui\" plan international cooperation project","award":["HZKY20220459"],"award-info":[{"award-number":["HZKY20220459"]}]},{"name":"Young Innovation Teams of Universities in Shandong Province","award":["2024KJN003"],"award-info":[{"award-number":["2024KJN003"]}]},{"name":"Young Talent of Lifting engineering for Science and Technology in Shandong, China","award":["SDAST2025QTA006"],"award-info":[{"award-number":["SDAST2025QTA006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02065-2","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:32:35Z","timestamp":1773725555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Critical roles of Hedgehog signaling pathway in regulating the multidrug resistance of ovarian cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Ruixue","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"3","key":"2065_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2065_CR2","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, et al. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.","journal-title":"Nat Rev Dis Primers"},{"key":"2065_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-031-58311-7_4","volume":"1452","author":"M Mehrotra","year":"2024","unstructured":"Mehrotra M, et al. Drug-resistant epithelial ovarian cancer: current and future perspectives. Adv Exp Med Biol. 2024;1452:65\u201396.","journal-title":"Adv Exp Med Biol"},{"issue":"14","key":"2065_CR4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W. Ovarian cancer: a review. JAMA. 2025;334(14):1278\u201391.","journal-title":"JAMA"},{"issue":"3","key":"2065_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/ijgc-00009577-200705000-00008","volume":"17","author":"A Santillan","year":"2007","unstructured":"Santillan A, et al. Differences of chemoresistance assay between invasive micropapillary\/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer. 2007;17(3):601\u20136.","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 5","key":"2065_CR6","doi-asserted-by":"publisher","first-page":"v181","DOI":"10.1093\/annonc\/mdj978","volume":"17","author":"RF Ozols","year":"2006","unstructured":"Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006;17(Suppl 5):v181\u20137.","journal-title":"Ann Oncol"},{"issue":"9951","key":"2065_CR7","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, et al. Ovarian Cancer. Lancet. 2014;384(9951):1376\u201388.","journal-title":"Lancet"},{"key":"2065_CR8","doi-asserted-by":"crossref","unstructured":"Babaier, A., and P. Ghatage. Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics (Basel) 2020;10(1):52.","DOI":"10.3390\/diagnostics10010052"},{"issue":"12","key":"2065_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani AC, et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20(12):820\u201342.","journal-title":"Nat Rev Clin Oncol"},{"key":"2065_CR10","doi-asserted-by":"crossref","unstructured":"Doheny, Daniel, et al. Hedgehog Signaling and Truncated Gli1 in Cancer. Cells 2020;9 (9):2114.","DOI":"10.3390\/cells9092114"},{"issue":"8","key":"2065_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1042\/CS20180845","volume":"133","author":"M Katoh","year":"2019","unstructured":"Katoh M. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. Clin Sci. 2019;133(8):953\u201370.","journal-title":"Clin Sci"},{"issue":"1","key":"2065_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3390\/ijms14011179","volume":"14","author":"J Szkandera","year":"2013","unstructured":"Szkandera J, et al. Hedgehog signaling pathway in ovarian cancer. Int J Mol Sci. 2013;14(1):1179\u201396.","journal-title":"Int J Mol Sci"},{"key":"2065_CR13","doi-asserted-by":"crossref","unstructured":"Du, Jing, et al. Disruption of Shh Signaling Cascade by Sbe Attenuates Lung Cancer Progression and Sensitizes Ddp Treatment. Scientific Reports 2017;7 (1):1899.","DOI":"10.1038\/s41598-017-02063-x"},{"issue":"6","key":"2065_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00210-023-02386-9","volume":"396","author":"X Yu","year":"2023","unstructured":"Yu X, et al. Antitumor activity and mechanism of cucurbitacin B in A549\/Ddp cells. Naunyn-Schmiedebergs Arch Pharmacol. 2023;396(6):1095\u2013103.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"18","key":"2065_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41388-023-02883-4","volume":"43","author":"W Chen","year":"2023","unstructured":"Chen W, et al. Lncrna Mir31hg fosters stemness malignant features of non-small cell lung cancer via H3k4me1- and H3k27ace-mediated Gli2 expression. Oncogene. 2023;43(18):1328\u201340.","journal-title":"Oncogene"},{"key":"2065_CR16","doi-asserted-by":"crossref","unstructured":"Dong, Hongliang, et al. N6-Methyladenine-mediated aberrant activation of the Lncrna Sox2ot-Gli1 loop promotes non-small-cell lung cancer stemness. Cell Death Discovery 2023;9 (1):149.","DOI":"10.1038\/s41420-023-01442-w"},{"key":"2065_CR17","doi-asserted-by":"crossref","unstructured":"Chen, Wei-Wei, et al. Scutellariabarbata D. Don extraction selectively targets stemness-prone Nsclc cells by attenuating Sox2\/Smo\/Gli1 network loop. J Ethnopharmacol 2021;265:113295.","DOI":"10.1016\/j.jep.2020.113295"},{"issue":"5","key":"2065_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00280-018-3561-4","volume":"81","author":"W Chen","year":"2018","unstructured":"Chen W, et al. Sodium selenite attenuates lung adenocarcinoma progression by repressing Sox2-mediated stemness. Cancer Chemother Pharmacol. 2018;81(5):885\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2065_CR19","doi-asserted-by":"crossref","unstructured":"Avery, Justin T., Ruowen Zhang, and Rebecca J. Boohaker. Gli1: a therapeutic target for cancer. Front Oncol 2021;11:673154.","DOI":"10.3389\/fonc.2021.673154"},{"issue":"9","key":"2065_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.neo.2021.06.010","volume":"23","author":"C Mani","year":"2021","unstructured":"Mani C, et al. Hedgehog\/Gli1 transcriptionally regulates Fancd2 in ovarian tumor cells: its inhibition induces Hr-deficiency and synergistic lethality with Parp inhibition. Neoplasia. 2021;23(9):1002\u201315.","journal-title":"Neoplasia"},{"issue":"6","key":"2065_CR21","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.3892\/or.2020.7798","volume":"44","author":"H Zhang","year":"2020","unstructured":"Zhang H, et al. The hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein\u00a01 in ovarian cancer. Oncol Rep. 2020;44(6):2610\u201320.","journal-title":"Oncol Rep"},{"issue":"23","key":"2065_CR22","first-page":"1673","volume":"25","author":"KX Yin","year":"2018","unstructured":"Yin KX, Fu ZQ, Chen YQ. Mechanism of paclitaxel resistance in ovarian cancer. Chin J Cancer Prev Treat. 2018;25(23):1673\u20138 ((in Chinese)).","journal-title":"Chin J Cancer Prev Treat"},{"issue":"05","key":"2065_CR23","first-page":"463","volume":"39","author":"Y Liu","year":"2024","unstructured":"Liu Y, Huang L. Research advances in platinum resistance and its treatment in ovarian cancer. J Precision Med. 2024;39(05):463\u20137 ((in Chinese)).","journal-title":"J Precision Med"},{"key":"2065_CR24","doi-asserted-by":"crossref","unstructured":"Yang, L., et al. Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review). Oncol Rep 2022;47(4):82.","DOI":"10.3892\/or.2022.8293"},{"issue":"10","key":"2065_CR25","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.33727","volume":"149","author":"AY Coughlan","year":"2021","unstructured":"Coughlan AY, Testa G. Exploiting epigenetic dependencies in ovarian cancer therapy. Int J Cancer. 2021;149(10):1732\u201343.","journal-title":"Int J Cancer"},{"key":"2065_CR26","doi-asserted-by":"crossref","unstructured":"Cornelison, R., D. C. Llaneza, and C. N. Landen. Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review. Int J Mol Sci 2017;18(10):2171.","DOI":"10.3390\/ijms18102171"},{"issue":"33","key":"2065_CR27","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi J, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (Ninja). J Clin Oncol. 2021;39(33):3671\u201381.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2065_CR28","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdx228","volume":"28","author":"A Bamias","year":"2017","unstructured":"Bamias A, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the Aurelia trial. Ann Oncol. 2017;28(8):1842\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"2065_CR29","doi-asserted-by":"publisher","first-page":"v188","DOI":"10.1093\/annonc\/mdj979","volume":"17","author":"D Lorusso","year":"2006","unstructured":"Lorusso D, et al. Role of gemcitabine in ovarian cancer treatment. Ann Oncol. 2006;17(Suppl 5):v188\u201394.","journal-title":"Ann Oncol"},{"issue":"1","key":"2065_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76\u201382.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2065_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","volume":"11","author":"N Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 N, Carr\u00e9 M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413\u201331.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2065_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","volume":"7","author":"E Zsiros","year":"2021","unstructured":"Zsiros E, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2021;7(1):78\u201385.","journal-title":"JAMA Oncol"},{"issue":"24","key":"2065_CR33","first-page":"4227","volume":"37","author":"J Chen","year":"2024","unstructured":"Chen J. To investigate the effect of olaparib combined with cisplatin and cyclophosphamide chemotherapy on objective response rate and serum tumor markers in patients with ovarian cancer. J Med Theory Pract. 2024;37(24):4227\u20139 ((in Chinese)).","journal-title":"J Med Theory Pract"},{"issue":"6","key":"2065_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14740338.2017.1325871","volume":"16","author":"D Lorusso","year":"2017","unstructured":"Lorusso D, et al. The safety of antiangiogenic agents and Parp inhibitors in platinum-sensitive recurrent ovarian cancer. Expert Opin Drug Saf. 2017;16(6):687\u201396.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2065_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2065_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2015.07.008","volume":"138","author":"W Graybill","year":"2015","unstructured":"Graybill W, et al. State of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol. 2015;138(2):223\u20136.","journal-title":"Gynecol Oncol"},{"issue":"30","key":"2065_CR37","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.2014.57.4574","volume":"32","author":"KE Oliver","year":"2014","unstructured":"Oliver KE, McGuire WP. Ovarian cancer and antiangiogenic therapy: caveat emptor. J Clin Oncol. 2014;32(30):3353\u20136.","journal-title":"J Clin Oncol"},{"key":"2065_CR38","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-Vegf therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857\u201367.","journal-title":"Drug Des Devel Ther"},{"key":"2065_CR39","doi-asserted-by":"publisher","first-page":"4880355","DOI":"10.1155\/2022\/4880355","volume":"2022","author":"C Jin","year":"2022","unstructured":"Jin C, et al. Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy. J Oncol. 2022;2022:4880355.","journal-title":"J Oncol"},{"issue":"2","key":"2065_CR40","first-page":"304","volume":"5","author":"M Ortiz","year":"2022","unstructured":"Ortiz M, et al. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022;5(2):304\u201316.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"2065_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","volume":"18","author":"DM O'Malley","year":"2023","unstructured":"O\u2019Malley DM, et al. Parp inhibitors in ovarian cancer: a review. Target Oncol. 2023;18(4):471\u2013503.","journal-title":"Target Oncol"},{"issue":"03","key":"2065_CR42","first-page":"48","volume":"30","author":"WJ Yu","year":"2023","unstructured":"Yu WJ, et al. Research progress on the mechanism of ovarian cancer resistance to poly (ADP-ribose) polymerase inhibitors. China Modern Med. 2023;30(03):48\u201352 ((in Chinese)).","journal-title":"China Modern Med"},{"issue":"15","key":"2065_CR43","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","volume":"83","author":"V Garg","year":"2023","unstructured":"Garg V, Oza AM. Treatment of ovarian cancer beyond parp inhibition: current and future options. Drugs. 2023;83(15):1365\u201385.","journal-title":"Drugs"},{"issue":"4","key":"2065_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14728214.2020.1836155","volume":"25","author":"D Lorusso","year":"2020","unstructured":"Lorusso D, et al. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. Expert Opin Emerg Drugs. 2020;25(4):445\u201353.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"8","key":"2065_CR45","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.drudis.2023.103666","volume":"28","author":"Z Peng","year":"2023","unstructured":"Peng Z, et al. Pd-1\/Pd-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities. Drug Discov Today. 2023;28(8):103666.","journal-title":"Drug Discov Today"},{"issue":"2","key":"2065_CR46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.20517\/cdr.2023.13","volume":"6","author":"WH Yoon","year":"2023","unstructured":"Yoon WH, DeFazio A, Kasherman L. Immune checkpoint inhibitors in ovarian cancer: where do we go from here? Cancer Drug Resist. 2023;6(2):358\u201377.","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"2065_CR47","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-22-2032","volume":"29","author":"CN Landen","year":"2023","unstructured":"Landen CN, et al. Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the imagyn050 randomized clinical trial. Clin Cancer Res. 2023;29(9):1698\u2013707.","journal-title":"Clin Cancer Res"},{"key":"2065_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ygyno.2023.06.018","volume":"177","author":"S Pignata","year":"2023","unstructured":"Pignata S, et al. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III imagyn050\/Gog 3015\/Engot-Ov39 trial of atezolizumab for newly diagnosed stage III\/IV ovarian cancer. Gynecol Oncol. 2023;177:20\u201331.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2065_CR49","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1158\/1078-0432.CCR-23-0048","volume":"29","author":"DH Al-Rawi","year":"2023","unstructured":"Al-Rawi DH, Rusk N, Friedman CF. The search for genomic biomarkers of response to immunotherapy in ovarian cancer. Clin Cancer Res. 2023;29(9):1645\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2065_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2018.11.025","volume":"152","author":"JL Boland","year":"2019","unstructured":"Boland JL, et al. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecol Oncol. 2019;152(2):251\u20138.","journal-title":"Gynecol Oncol"},{"issue":"34","key":"2065_CR51","doi-asserted-by":"publisher","first-page":"55771","DOI":"10.18632\/oncotarget.9908","volume":"7","author":"J Deng","year":"2016","unstructured":"Deng J, et al. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget. 2016;7(34):55771\u201388.","journal-title":"Oncotarget"},{"issue":"1","key":"2065_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, et al. Emt: 2016. Cell. 2016;166(1):21\u201345.","journal-title":"Cell"},{"key":"2065_CR53","doi-asserted-by":"crossref","unstructured":"Du, B., and J. S. Shim. Targeting Epithelial-Mesenchymal Transition (Emt) to overcome drug resistance in cancer. Molecules 2016;21(7):965.","DOI":"10.3390\/molecules21070965"},{"key":"2065_CR54","doi-asserted-by":"crossref","unstructured":"Jin, W. Role of Jak\/Stat3 Signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition. Cells 2020;9(1):217.","DOI":"10.3390\/cells9010217"},{"issue":"2","key":"2065_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2065_CR56","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12032-014-0368-y","volume":"32","author":"Z Ke","year":"2015","unstructured":"Ke Z, et al. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating Pi3k\/Akt pathway. Med Oncol. 2015;32(1):368.","journal-title":"Med Oncol"},{"issue":"4","key":"2065_CR57","doi-asserted-by":"publisher","first-page":"990","DOI":"10.7150\/jca.26478","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, et al. Aberrant activation of hedgehog signalling promotes cell migration and invasion via matrix metalloproteinase-7 in ovarian cancer cells. J Cancer. 2019;10(4):990\u20131003.","journal-title":"J Cancer"},{"issue":"2","key":"2065_CR58","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3892\/ijo.2017.4044","volume":"51","author":"Y Yang","year":"2017","unstructured":"Yang Y, et al. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer. Int J Oncol. 2017;51(2):515\u201324.","journal-title":"Int J Oncol"},{"issue":"1","key":"2065_CR59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3892\/ijmm.2013.1538","volume":"33","author":"P Zhang","year":"2014","unstructured":"Zhang P, et al. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med. 2014;33(1):151\u20139.","journal-title":"Int J Mol Med"},{"key":"2065_CR60","doi-asserted-by":"crossref","unstructured":"Loret, N., et al. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers (Basel) 2019;11(6):838.","DOI":"10.3390\/cancers11060838"},{"key":"2065_CR61","doi-asserted-by":"crossref","unstructured":"Suzuki, T., et al. Role of epithelial-mesenchymal transition factor snai1 and its targets in ovarian cancer aggressiveness. J Cancer Metastasis Treat 2023;9:25.","DOI":"10.20517\/2394-4722.2023.34"},{"issue":"1","key":"2065_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41556-018-0196-y","volume":"21","author":"MP Stemmler","year":"2019","unstructured":"Stemmler MP, et al. Non-redundant functions of Emt transcription factors. Nat Cell Biol. 2019;21(1):102\u201312.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2065_CR63","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ncb2976","volume":"16","author":"A Puisieux","year":"2014","unstructured":"Puisieux A, Brabletz T, Caramel J. Oncogenic roles of Emt-inducing transcription factors. Nat Cell Biol. 2014;16(6):488\u201394.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2065_CR64","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ncb3520","volume":"19","author":"MA Nieto","year":"2017","unstructured":"Nieto MA. Context-specific roles of Emt programmes in cancer cell dissemination. Nat Cell Biol. 2017;19(5):416\u20138.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2065_CR65","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbcan.2017.06.006","volume":"1868","author":"S Goossens","year":"2017","unstructured":"Goossens S, et al. Emt transcription factors in cancer development re-evaluated: beyond Emt and Met. Biochim Biophys Acta Rev Cancer. 2017;1868(2):584\u201391.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"2065_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B De Craene","year":"2013","unstructured":"De Craene B, Berx G. Regulatory networks defining Emt during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97\u2013110.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2065_CR67","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.bcp.2012.08.019","volume":"84","author":"S Mozzetti","year":"2012","unstructured":"Mozzetti S, et al. Gli family transcription factors are drivers of patupilone resistance in ovarian cancer. Biochem Pharmacol. 2012;84(11):1409\u201318.","journal-title":"Biochem Pharmacol"},{"issue":"7211","key":"2065_CR68","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature07275","volume":"455","author":"RL Yauch","year":"2008","unstructured":"Yauch RL, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455(7211):406\u201310.","journal-title":"Nature"},{"issue":"15","key":"2065_CR69","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1158\/0008-5472.CAN-09-0756","volume":"69","author":"JW Theunissen","year":"2009","unstructured":"Theunissen JW, de Sauvage FJ. Paracrine hedgehog signaling in cancer. Cancer Res. 2009;69(15):6007\u201310.","journal-title":"Cancer Res"},{"issue":"4","key":"2065_CR70","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1158\/0008-5472.CAN-11-2681","volume":"72","author":"E Heller","year":"2012","unstructured":"Heller E, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72(4):897\u2013907.","journal-title":"Cancer Res"},{"issue":"1","key":"2065_CR71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, et al. Parp inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.","journal-title":"Mol Cancer"},{"issue":"5-6","key":"2065_CR72","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade D. Parp and Parg inhibitors in cancer treatment. Genes Dev. 2020;34(5\u20136):360\u201394.","journal-title":"Genes Dev"},{"issue":"1","key":"2065_CR73","doi-asserted-by":"publisher","first-page":"7430","DOI":"10.1038\/s41467-023-42850-x","volume":"14","author":"L Tao","year":"2023","unstructured":"Tao L, et al. Repression of Lsd1 potentiates homologous recombination-proficient ovarian cancer to Parp inhibitors through down-regulation of Brca1\/2 and Rad51. Nat Commun. 2023;14(1):7430.","journal-title":"Nat Commun"},{"issue":"17","key":"2065_CR74","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1158\/1078-0432.CCR-15-0088","volume":"21","author":"KS Tewari","year":"2015","unstructured":"Tewari KS, Eskander RN, Monk BJ. Development of olaparib for Brca-deficient recurrent epithelial ovarian cancer. Clin Cancer Res. 2015;21(17):3829\u201335.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2065_CR75","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","volume":"75","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi R, et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and Parp inhibitor resistance. Cancer Res. 2015;75(4):628\u201334.","journal-title":"Cancer Res"},{"issue":"11","key":"2065_CR76","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137\u201354.","journal-title":"Cancer Discov"},{"issue":"8","key":"2065_CR77","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang HHY, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495\u2013506.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2065_CR78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-020-00197-9","volume":"10","author":"Z Wu","year":"2021","unstructured":"Wu Z, Nicoll M, Ingham RJ. Ap-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical Hodgkin lymphoma and Alk+\u2009Alcl. Exp Hematol Oncol. 2021;10(1):4.","journal-title":"Exp Hematol Oncol"},{"issue":"36","key":"2065_CR79","doi-asserted-by":"publisher","first-page":"23419","DOI":"10.1074\/jbc.273.36.23419","volume":"273","author":"Q Li","year":"1998","unstructured":"Li Q, et al. Cisplatin induction of Ercc-1 Mrna expression in A2780\/Cp70 human ovarian cancer cells. J Biol Chem. 1998;273(36):23419\u201325.","journal-title":"J Biol Chem"},{"issue":"4","key":"2065_CR80","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0006-2952(98)00291-3","volume":"57","author":"Q Li","year":"1999","unstructured":"Li Q, et al. Modulation of excision repair cross complementation group 1 (Ercc-1) mrna expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol. 1999;57(4):347\u201353.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2065_CR81","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/sj.cgt.7700409","volume":"9","author":"M Bonovich","year":"2002","unstructured":"Bonovich M, et al. Adenoviral delivery of a-Fos, an Ap-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther. 2002;9(1):62\u201370.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"2065_CR82","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","volume":"24","author":"E Reed","year":"1998","unstructured":"Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331\u201344.","journal-title":"Cancer Treat Rev"},{"issue":"44","key":"2065_CR83","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1038\/onc.2011.610","volume":"31","author":"K Kudo","year":"2012","unstructured":"Kudo K, et al. Inhibition of Gli1 results in altered C-Jun activation, inhibition of cisplatin-induced upregulation of Ercc1, Xpd and Xrcc1, and inhibition of platinum-DNA adduct repair. Oncogene. 2012;31(44):4718\u201324.","journal-title":"Oncogene"},{"issue":"18","key":"2065_CR84","doi-asserted-by":"publisher","first-page":"10342","DOI":"10.1093\/nar\/gkaa733","volume":"48","author":"TD Lama-Sherpa","year":"2020","unstructured":"Lama-Sherpa TD, et al. Hedgehog signaling enables repair of ribosomal DNA double-strand breaks. Nucleic Acids Res. 2020;48(18):10342\u201352.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2065_CR85","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3892\/ijo.2013.2222","volume":"44","author":"L Amable","year":"2014","unstructured":"Amable L, et al. Gli1 upregulates C-Jun through a specific 130-Kda isoform. Int J Oncol. 2014;44(3):655\u201361.","journal-title":"Int J Oncol"},{"issue":"2","key":"2065_CR86","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3892\/or.2014.3257","volume":"32","author":"L Amable","year":"2014","unstructured":"Amable L, et al. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug. Oncol Rep. 2014;32(2):469\u201374.","journal-title":"Oncol Rep"},{"issue":"8","key":"2065_CR87","first-page":"625","volume":"53","author":"Y Chen","year":"2014","unstructured":"Chen Y, Bieber MM, Teng NN. Hedgehog signaling regulates drug sensitivity by targeting Abc transporters Abcb1 and Abcg2 in epithelial ovarian cancer. Mol Carcinog. 2014;53(8):625\u201334.","journal-title":"Mol Carcinog"},{"issue":"6","key":"2065_CR88","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.3892\/or.2020.7798","volume":"44","author":"H Zhang","year":"2020","unstructured":"Zhang H, et al. The hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer. Oncol Rep. 2020;44(6):2610\u201320.","journal-title":"Oncol Rep"},{"issue":"4","key":"2065_CR89","first-page":"5155","volume":"15","author":"W Zhang","year":"2018","unstructured":"Zhang W, et al. Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-Abcg2 signaling pathway. Oncol Lett. 2018;15(4):5155\u201360.","journal-title":"Oncol Lett"},{"issue":"11","key":"2065_CR90","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1541-7786.MCR-11-0578","volume":"10","author":"M Bidet","year":"2012","unstructured":"Bidet M, et al. The Hedgehog receptor patched functions in multidrug transport and chemotherapy resistance. Mol Cancer Res. 2012;10(11):1496\u2013508.","journal-title":"Mol Cancer Res"},{"key":"2065_CR91","doi-asserted-by":"publisher","unstructured":"\u8d75\u96c5\u851a.GLI1\u8c03\u63a7\u80bf\u7624\u5e72\u7ec6\u80de\u7279\u6027\u5728\u5316\u7597\u540e\u5375\u5de2\u764c\u590d\u53d1\u548c\u8f6c\u79fb\u4e2d\u4f5c\u7528\u53ca\u673a\u5236\u7814\u7a76[D].\u5409\u6797\u5927\u5b66,2021. https:\/\/doi.org\/10.27162\/d.cnki.gjlin.2021.002380.","DOI":"10.27162\/d.cnki.gjlin.2021.002380"},{"issue":"7467","key":"2065_CR92","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346\u201354.","journal-title":"Nature"},{"issue":"11","key":"2065_CR93","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"4","key":"2065_CR94","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395\u2013406.","journal-title":"J Cell Biol"},{"key":"2065_CR95","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.drup.2020.100715","volume":"53","author":"N Erin","year":"2020","unstructured":"Erin N, et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.","journal-title":"Drug Resist Updat"},{"key":"2065_CR96","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pharmthera.2016.09.011","volume":"168","author":"KN Atretkhany","year":"2016","unstructured":"Atretkhany KN, et al. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther. 2016;168:98\u2013112.","journal-title":"Pharmacol Ther"},{"issue":"7223","key":"2065_CR97","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nature07445","volume":"456","author":"C Stockmann","year":"2008","unstructured":"Stockmann C, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008;456(7223):814\u20138.","journal-title":"Nature"},{"issue":"7335","key":"2065_CR98","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","volume":"470","author":"W Tan","year":"2011","unstructured":"Tan W, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through Rankl-Rank signalling. Nature. 2011;470(7335):548\u201353.","journal-title":"Nature"},{"issue":"34","key":"2065_CR99","doi-asserted-by":"publisher","first-page":"28745","DOI":"10.1074\/jbc.M112.351379","volume":"287","author":"PK Kandala","year":"2012","unstructured":"Kandala PK, Srivastava SK. Diindolylmethane-Mediated Gli1 protein suppression induces Anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J Biol Chem. 2012;287(34):28745\u201354.","journal-title":"J Biol Chem"},{"issue":"3","key":"2065_CR100","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1015312119693","volume":"7","author":"J Grossmann","year":"2002","unstructured":"Grossmann J. Molecular mechanisms of \u201cdetachment-induced apoptosis\u2013anoikis.\u201d Apoptosis. 2002;7(3):247\u201360.","journal-title":"Apoptosis"},{"issue":"2","key":"2065_CR101","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177\u201385.","journal-title":"Cancer Lett"},{"key":"2065_CR102","doi-asserted-by":"crossref","unstructured":"Reavis, H. D., et al. norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. JCI Insight 2024;9 (5):e170961.","DOI":"10.1172\/jci.insight.170961"},{"issue":"1","key":"2065_CR103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","volume":"132","author":"B Levine","year":"2008","unstructured":"Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27\u201342.","journal-title":"Cell"},{"key":"2065_CR104","doi-asserted-by":"crossref","unstructured":"Ferraresi, A., et al. Resveratrol contrasts Lpa-induced ovarian cancer cell migration and platinum resistance by rescuing hedgehog-mediated autophagy. Cells 2021;10(11):3213.","DOI":"10.3390\/cells10113213"},{"issue":"4","key":"2065_CR105","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/med.21473","volume":"38","author":"C Thuwajit","year":"2018","unstructured":"Thuwajit C, et al. The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: autophagy plays a role. Med Res Rev. 2018;38(4):1235\u201354.","journal-title":"Med Res Rev"},{"key":"2065_CR106","doi-asserted-by":"crossref","unstructured":"Thongchot, S., et al. Interleukin\u20118 released by cancer\u2011associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells. Int J Oncol 2021;58(5):14.","DOI":"10.3892\/ijo.2021.5194"},{"issue":"2","key":"2065_CR107","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/med.21531","volume":"39","author":"H Folkerts","year":"2019","unstructured":"Folkerts H, et al. The multifaceted role of autophagy in cancer and the microenvironment. Med Res Rev. 2019;39(2):517\u201360.","journal-title":"Med Res Rev"},{"key":"2065_CR108","doi-asserted-by":"crossref","unstructured":"Xu, Y. Lysophospholipid signaling in the epithelial ovarian cancer tumor microenvironment. Cancers (Basel) 2018;10(7):227.","DOI":"10.3390\/cancers10070227"},{"key":"2065_CR109","doi-asserted-by":"publisher","first-page":"1171418","DOI":"10.3389\/fonc.2023.1171418","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang J, et al. The emerging roles of Hedgehog signaling in tumor immune microenvironment. Front Oncol. 2023;13:1171418.","journal-title":"Front Oncol"},{"issue":"1","key":"2065_CR110","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12943-025-02345-3","volume":"24","author":"H Alizadeh","year":"2025","unstructured":"Alizadeh H, et al. A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities. Mol Cancer. 2025;24(1):135.","journal-title":"Mol Cancer"},{"issue":"2","key":"2065_CR111","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ygyno.2020.09.002","volume":"159","author":"G Gunay","year":"2020","unstructured":"Gunay G, et al. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration. Gynecol Oncol. 2020;159(2):563\u201372.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2065_CR112","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/1878-0261.13556","volume":"18","author":"N Gendrau-Sanclemente","year":"2024","unstructured":"Gendrau-Sanclemente N, et al. Ovarian cancer relies on the Pdgfr\u03b2-fibronectin axis for tumorsphere formation and metastatic spread. Mol Oncol. 2024;18(1):136\u201355.","journal-title":"Mol Oncol"},{"issue":"1","key":"2065_CR113","first-page":"117","volume":"17","author":"H Xing","year":"2007","unstructured":"Xing H, et al. Knock-down of P-glycoprotein reverses Taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep. 2007;17(1):117\u201322.","journal-title":"Oncol Rep"},{"issue":"1","key":"2065_CR114","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield K, et al. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113(1):143\u20138.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2065_CR115","first-page":"2388","volume":"57","author":"A Frankel","year":"1997","unstructured":"Frankel A, Buckman R, Kerbel RS. Abrogation of Taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997;57(12):2388\u201393.","journal-title":"Cancer Res"},{"issue":"4","key":"2065_CR116","first-page":"797","volume":"39","author":"A Ray","year":"2011","unstructured":"Ray A, et al. Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Int J Oncol. 2011;39(4):797\u2013804.","journal-title":"Int J Oncol"},{"key":"2065_CR117","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.biocel.2018.11.012","volume":"106","author":"Z Pieterse","year":"2019","unstructured":"Pieterse Z, et al. Ovarian cancer stem cells and their role in drug resistance. Int J Biochem Cell Biol. 2019;106:117\u201326.","journal-title":"Int J Biochem Cell Biol"},{"issue":"10","key":"2065_CR118","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. Emt, Cscs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2065_CR119","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.18632\/oncotarget.6870","volume":"7","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, et al. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a Bmp4\/Hh signaling loop. Oncotarget. 2016;7(6):6916\u201332.","journal-title":"Oncotarget"},{"key":"2065_CR120","doi-asserted-by":"crossref","unstructured":"Raghavan, S., et al. Carcinoma-associated mesenchymal stem cells promote chemoresistance in ovarian cancer stem cells via Pdgf Signaling. Cancers (Basel) 2020;12(8):2063.","DOI":"10.3390\/cancers12082063"},{"key":"2065_CR121","doi-asserted-by":"crossref","unstructured":"Zhao, H., et al. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein nanog. Mol Med Rep 2021;23(2):128.","DOI":"10.3892\/mmr.2020.11767"},{"issue":"9","key":"2065_CR122","first-page":"1121","volume":"27","author":"VC Mak","year":"2012","unstructured":"Mak VC, et al. Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol. 2012;27(9):1121\u201330.","journal-title":"Histol Histopathol"},{"key":"2065_CR123","doi-asserted-by":"crossref","unstructured":"Robinson, M., et al. Characterization of Sox2, Oct4 and Nanog in ovarian cancer tumor-initiating cells. Cancers (Basel) 2021;13(2):262.","DOI":"10.3390\/cancers13020262"},{"key":"2065_CR124","doi-asserted-by":"publisher","unstructured":"Song,Xueling, et al. Activation of Hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors. Oncology Letters (2018). https:\/\/doi.org\/10.3892\/ol.2018.8008.","DOI":"10.3892\/ol.2018.8008"},{"issue":"1","key":"2065_CR125","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I","volume":"73","author":"AN Corps","year":"1997","unstructured":"Corps AN, Sowter HM, Smith SK. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of C-Met. Int J Cancer. 1997;73(1):151\u20135.","journal-title":"Int J Cancer"},{"issue":"5","key":"2065_CR126","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1210\/en.2005-1404","volume":"147","author":"HY Zhou","year":"2006","unstructured":"Zhou HY, Wong AS. Activation of P70s6k induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 2006;147(5):2557\u201366.","journal-title":"Endocrinology"},{"issue":"2","key":"2065_CR127","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1593\/neo.91438","volume":"12","author":"MK Tang","year":"2010","unstructured":"Tang MK, et al. C-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1\/2. Neoplasia. 2010;12(2):128\u201338.","journal-title":"Neoplasia"},{"issue":"6","key":"2065_CR128","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41419-022-04976-6","volume":"13","author":"AA Hassan","year":"2022","unstructured":"Hassan AA, et al. Ascitic fluid shear stress in concert with hepatocyte growth factor drive stemness and chemoresistance of ovarian cancer cells via the C-Met-Pi3k\/Akt-Mir-199a-3p signaling pathway. Cell Death Dis. 2022;13(6):537.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2065_CR129","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/ijc.28464","volume":"134","author":"S Pavan","year":"2014","unstructured":"Pavan S, et al. Hsp27 is required for invasion and metastasis triggered by hepatocyte growth factor. Int J Cancer. 2014;134(6):1289\u201399.","journal-title":"Int J Cancer"},{"issue":"24","key":"2065_CR130","doi-asserted-by":"publisher","first-page":"10197","DOI":"10.1158\/0008-5472.CAN-08-2091","volume":"68","author":"S Mozzetti","year":"2008","unstructured":"Mozzetti S, et al. Molecular mechanisms of patupilone resistance. Cancer Res. 2008;68(24):10197\u2013204.","journal-title":"Cancer Res"},{"issue":"2","key":"2065_CR131","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","volume":"9","author":"P S\u00e8ve","year":"2008","unstructured":"S\u00e8ve P, Dumontet C. Is class Iii beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008;9(2):168\u201375.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2065_CR132","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2174\/156800907783220453","volume":"7","author":"C Ferlini","year":"2007","unstructured":"Ferlini C, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: does Tubb3 work? Curr Cancer Drug Targets. 2007;7(8):704\u201312.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"2065_CR133","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/nar\/gky058","volume":"46","author":"Y Okamoto","year":"2018","unstructured":"Okamoto Y, et al. Replication stress induces accumulation of Fancd2 at central region of large fragile genes. Nucleic Acids Res. 2018;46(6):2932\u201344.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"2065_CR134","doi-asserted-by":"publisher","first-page":"11837","DOI":"10.1093\/nar\/gkx847","volume":"45","author":"EL Thompson","year":"2017","unstructured":"Thompson EL, et al. Fanci and Fancd2 have common as well as independent functions during the cellular replication stress response. Nucleic Acids Res. 2017;45(20):11837\u201357.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2065_CR135","doi-asserted-by":"publisher","first-page":"12959","DOI":"10.1007\/s13277-016-5207-7","volume":"37","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ng F, Tang BL. Rab23 activities and human cancer-emerging connections and mechanisms. Tumour Biol. 2016;37(10):12959\u201367.","journal-title":"Tumour Biol"},{"issue":"5","key":"2065_CR136","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.18632\/oncotarget.6701","volume":"7","author":"Q Jian","year":"2016","unstructured":"Jian Q, et al. Rab23 promotes squamous cell carcinoma cell migration and invasion via integrin \u03921\/Rac1 pathway. Oncotarget. 2016;7(5):5342\u201352.","journal-title":"Oncotarget"},{"issue":"8","key":"2065_CR137","doi-asserted-by":"publisher","first-page":"11049","DOI":"10.1007\/s13277-016-4949-6","volume":"37","author":"M Wang","year":"2016","unstructured":"Wang M, Dong Q, Wang Y. Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1. Tumour Biol. 2016;37(8):11049\u201355.","journal-title":"Tumour Biol"},{"issue":"3","key":"2065_CR138","doi-asserted-by":"publisher","first-page":"811","DOI":"10.7150\/thno.29271","volume":"9","author":"J Cao","year":"2019","unstructured":"Cao J, et al. Rack1 promotes self-renewal and chemoresistance of cancer stem cells in human hepatocellular carcinoma through stabilizing Nanog. Theranostics. 2019;9(3):811\u201328.","journal-title":"Theranostics"},{"issue":"3","key":"2065_CR139","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/1078-0432.CCR-11-2188","volume":"18","author":"AD Steg","year":"2012","unstructured":"Steg AD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 2012;18(3):869\u201381.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2065_CR140","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.acthis.2013.09.007","volume":"116","author":"L Schreiber","year":"2014","unstructured":"Schreiber L, Raanan C, Amsterdam A. Cd24 and Nanog identify stem cells signature of ovarian epithelium and cysts that may develop to ovarian cancer. Acta Histochem. 2014;116(2):399\u2013406.","journal-title":"Acta Histochem"},{"key":"2065_CR141","doi-asserted-by":"crossref","unstructured":"Kakiuchi, S., et al. Nanog expression as a responsive biomarker during treatment with hedgehog signal inhibitor in acute myeloid leukemia. Int J Mol Sci 2017;18(3):486.","DOI":"10.3390\/ijms18030486"},{"issue":"2","key":"2065_CR142","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","volume":"35","author":"M Nakanishi","year":"2013","unstructured":"Nakanishi M, Rosenberg DW. Multifaceted roles of Pge2 in inflammation and cancer. Semin Immunopathol. 2013;35(2):123\u201337.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"2065_CR143","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2004.047100","volume":"55","author":"D Wang","year":"2006","unstructured":"Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55(1):115\u201322.","journal-title":"Gut"},{"issue":"26","key":"2065_CR144","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.2174\/138161212802083680","volume":"18","author":"V Sanz-Motilva","year":"2012","unstructured":"Sanz-Motilva V, Martorell-Calatayud A, Nagore E. Non-steroidal anti-inflammatory drugs and melanoma. Curr Pharm Des. 2012;18(26):3966\u201378.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"2065_CR145","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr1678","volume":"9","author":"LR Howe","year":"2007","unstructured":"Howe LR. Inflammation and breast cancer. Cyclooxygenase\/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9(4):210.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"2065_CR146","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/carcin\/bgp014","volume":"30","author":"A Greenhough","year":"2009","unstructured":"Greenhough A, et al. The Cox-2\/Pge2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377\u201386.","journal-title":"Carcinogenesis"},{"key":"2065_CR147","doi-asserted-by":"publisher","first-page":"794959","DOI":"10.3389\/fonc.2021.794959","volume":"11","author":"Q Wang","year":"2021","unstructured":"Wang Q, et al. Hedgehog-Gli2 signaling promotes chemoresistance in ovarian cancer cells by regulating Mdr1. Front Oncol. 2021;11:794959.","journal-title":"Front Oncol"},{"issue":"7","key":"2065_CR148","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1158\/1535-7163.MCT-11-1058","volume":"11","author":"AD Steg","year":"2012","unstructured":"Steg AD, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 2012;11(7):1587\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2065_CR149","first-page":"684","volume":"4","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. Cancer stem cells, epithelial-mesenchymal transition, Atp and their roles in drug resistance in cancer. Cancer Drug Resist. 2021;4(3):684\u2013709.","journal-title":"Cancer Drug Resist"},{"key":"2065_CR150","doi-asserted-by":"publisher","first-page":"1417532","DOI":"10.3389\/fphar.2024.1417532","volume":"15","author":"Q Yang","year":"2024","unstructured":"Yang Q, et al. Advances in the role of resveratrol and its mechanism of action in common gynecological tumors. Front Pharmacol. 2024;15:1417532.","journal-title":"Front Pharmacol"},{"key":"2065_CR151","doi-asserted-by":"crossref","unstructured":"Xu, X. L., et al. Resveratrol targets a variety of oncogenic and oncosuppressive signaling for ovarian cancer prevention and treatment. antioxidants (Basel) 2021;10(11):1718.","DOI":"10.3390\/antiox10111718"},{"issue":"16","key":"2065_CR152","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.18632\/oncotarget.2295","volume":"5","author":"AD Steg","year":"2014","unstructured":"Steg AD, et al. Proteasome inhibition reverses Hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget. 2014;5(16):7065\u201380.","journal-title":"Oncotarget"},{"issue":"12","key":"2065_CR153","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1248\/bpb.22.1355","volume":"22","author":"K Takara","year":"1999","unstructured":"Takara K, et al. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999;22(12):1355\u20139.","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"2065_CR154","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1248\/bpb.24.1032","volume":"24","author":"N Iida","year":"2001","unstructured":"Iida N, et al. Reversal effects of antifungal drugs on multidrug resistance in Mdr1-overexpressing Hela cells. Biol Pharm Bull. 2001;24(9):1032\u20136.","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"2065_CR155","doi-asserted-by":"publisher","first-page":"e19244","DOI":"10.1016\/j.heliyon.2023.e19244","volume":"9","author":"J Dong","year":"2023","unstructured":"Dong J, et al. Itraconazole inhibits proliferation, induces apoptosis, and reduces angiogenesis of hemangioma endothelial cells by downregulating the Hedgehog signaling pathway. Heliyon. 2023;9(9):e19244.","journal-title":"Heliyon"},{"issue":"4","key":"2065_CR156","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/cb600362d","volume":"2","author":"CR Chong","year":"2007","unstructured":"Chong CR, et al. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol. 2007;2(4):263\u201370.","journal-title":"ACS Chem Biol"},{"issue":"1","key":"2065_CR157","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","volume":"23","author":"J Kim","year":"2013","unstructured":"Kim J, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to Smoothened antagonists. Cancer Cell. 2013;23(1):23\u201334.","journal-title":"Cancer Cell"},{"issue":"4","key":"2065_CR158","first-page":"2007","volume":"34","author":"H Tsubamoto","year":"2014","unstructured":"Tsubamoto H, et al. Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma. Anticancer Res. 2014;34(4):2007\u201314.","journal-title":"Anticancer Res"},{"issue":"1","key":"2065_CR159","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.1038\/s41598-017-06510-7","volume":"7","author":"CH Choi","year":"2017","unstructured":"Choi CH, et al. The anti-cancer effects of itraconazole in epithelial ovarian cancer. Sci Rep. 2017;7(1):6552.","journal-title":"Sci Rep"},{"issue":"4","key":"2065_CR160","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388\u201399.","journal-title":"Cancer Cell"},{"key":"2065_CR161","doi-asserted-by":"crossref","unstructured":"Cosio, T., M. Di Prete, and E. Campione. Arsenic trioxide, itraconazole, all-trans retinoic acid and nicotinamide: a proof of concept for combined treatments with hedgehog inhibitors in advanced basal cell carcinoma. Biomedicines 2020;8(6):156.","DOI":"10.3390\/biomedicines8060156"},{"issue":"11","key":"2065_CR162","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/bjc.2017.116","volume":"116","author":"C Di Mauro","year":"2017","unstructured":"Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017;116(11):1425\u201335.","journal-title":"Br J Cancer"},{"issue":"40","key":"2065_CR163","doi-asserted-by":"publisher","first-page":"67315","DOI":"10.18632\/oncotarget.18621","volume":"8","author":"R Wei","year":"2017","unstructured":"Wei R, et al. Human Cafs promote lymphangiogenesis in ovarian cancer via the Hh-Vegf-C signaling axis. Oncotarget. 2017;8(40):67315\u201328.","journal-title":"Oncotarget"},{"issue":"1","key":"2065_CR164","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12964-024-01812-6","volume":"22","author":"R Liu","year":"2024","unstructured":"Liu R, et al. Interactions between hedgehog signaling pathway and the complex tumor microenvironment in breast cancer: current knowledge and therapeutic promises. Cell Commun Signal. 2024;22(1):432.","journal-title":"Cell Commun Signal"},{"issue":"34","key":"2065_CR165","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","volume":"37","author":"I Zerdes","year":"2018","unstructured":"Zerdes I, et al. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene. 2018;37(34):4639\u201361.","journal-title":"Oncogene"},{"issue":"3","key":"2065_CR166","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"2065_CR167","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jconrel.2022.08.054","volume":"350","author":"Y Zhai","year":"2022","unstructured":"Zhai Y, et al. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo\/immuno-arsenotherapy. J Control Release. 2022;350:761\u201376.","journal-title":"J Control Release"},{"key":"2065_CR168","doi-asserted-by":"crossref","unstructured":"Gampala, S., and J. Y. Yang. Hedgehog pathway inhibitors against tumor microenvironment. Cells 2021;10(11):3135.","DOI":"10.3390\/cells10113135"},{"issue":"23","key":"2065_CR169","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1158\/1078-0432.CCR-12-1796","volume":"18","author":"SB Kaye","year":"2012","unstructured":"Kaye SB, et al. A phase Ii, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18(23):6509\u201318.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2065_CR170","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s10637-017-0454-z","volume":"35","author":"A Stathis","year":"2017","unstructured":"Stathis A, et al. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2017;35(6):766\u201372.","journal-title":"Invest New Drugs"},{"key":"2065_CR171","doi-asserted-by":"crossref","unstructured":"Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol. 2016;27 Suppl 1(Suppl 1):i33\u2013i39.","DOI":"10.1093\/annonc\/mdw093"},{"issue":"D1","key":"2065_CR172","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, et al. Generic diagramming platform (Gdp): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53(D1):D1670\u20136.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02065-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02065-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02065-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:02:54Z","timestamp":1776996174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02065-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":172,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02065-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}